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What in your opinion was the most important 
paper published in your field in the past year?
DA: I have a relatively broad area of scientific interest en­
com passing cancer genetics, mouse genetics and genome 
sequencing. With my cancer hat on, the paper that 
impressed me most was by Sodir et al. [1], which showed 
that inhibition of Myc can cause cancer regression even 
in advanced tumors. This work illustrates the critical role 
that Myc plays in tumorigenesis, and clearly defines it as a 
therapeutic target. In terms of genome sequencing, I’m 
very impressed by some of the new de novo assembly 
algorithms, such as Li et al. [2], and I think our contri bu­
tion of sequencing mouse genomes, Keane et al. [3], is 
also important and will be of great use to the mouse genetics 
community. These sequences now make it possible to take a 
systems biology approach to mouse genetics and to link 
variants to phenotypes like never before.
BB: I would say the Foldit paper by David Baker’s group 
[4] because it shows a new model of research is possible. 
Some large­scale problems such as protein folding 
remain challenging to solve with just computational 
approaches, and the problem is too difficult for even 
experts to solve manually. However, by designing tools 
that can break such problems into puzzles that people, 
even non­experts, can play with in their spare time can 
provide cutting­edge solutions [5].
OH: In cancer genetics, two studies struck me this year. 
The first is the discovery and analysis of chromothripsis 
by Peter Campbell at the Sanger Institute [6]. This idea 
that some of the complex chromosomal rearrangements 
observed in cancer cells can come from a single 
catastrophic event, where an entire chromosome gets 
shattered and stuck back together at random, is 
astound ing. This has changed our understanding of cancer 
genome instability and repair: a truly novel finding and 
ground breaking idea [7]. The other cancer genetic study is 
the work of Inder Verma [8], Rusty Gage and colleagues at 
the Salk Institute [9] demonstrating a new function for 
BRCA1 involved in heterochromatin chromatin forma tion 
and repres sing satellite expression via the ubi quity lation of 
histone H2A [10]. This is beautiful work, which might 
deeply change our understanding of BRCA1’s role in cancer. 
This adds to the numerous and recent evidence of the 
importance of chromatin­modifying processes in cancer.
CH: One important recent paper is the work on the 
vaginal microbiome in reproductive­age women by 
Jacques Ravel and Larry Forney [11]. This is a very well­
structured and well­analyzed study that includes a variety 
of important findings. It establishes that diversity in the 
human microbiome is personalized and much more than 
‘noise’, and that following individual subjects longitu di­
nally can be extremely informative. It shows that the 
microbiota can be linked both to host phenotype and to 
host environment, but that neither of these alone is the 
whole story. In combination with other work, it shows 
that beyond community composition, the complete 
picture of microbial ecological structure, function and 
dynamics differs widely among humans and human body 
habitats. And it provides evidence that microbial com­
mu nity structure and its interaction with phenotype have 
potential links to genotype by way of racial background 
or ethnicity. Finally, all of these results together suggest 
ways by which personalized medicine can be influenced 
by the microbiome. Many of these are general results that 
have been shown in one or more previous studies, but 
this paper brings them all together nicely and applies 
them quite interpretably in the specific microbiological 
context of the vaginal community.
SL: There have been many interesting papers in the last 
year. One paper from the Dekker and Young labs [12] 
demonstrated that mediator can form a complex with 
cohesin to connect enhancers and core promoters of 
active genes in mouse embryonic stem cells. Predicting 
targets from transcription factor ChIP­seq has been a 
challenging problem, and perhaps mediator and cohesin 
binding could offer some insights into which bindings are 
functional with transcriptional outcomes. Another paper, 
from Howard Chang’s group [13], developed a new tech­
nique called ‘ChIRP­seq’ to identify the in vivo genome­
wide location of long non­coding RNAs and understand 
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their chromatin regulation functions. The Chang lab has 
shown exceptional ingenuity in both genomic technology 
development and biological mechanism discovery in 
recent years. A third paper, from Peter Laird’s group [14], 
showed that many cancer samples have small regions of 
hypermethylation within bigger domains of hypomethy­
la tion, and these domains coincide with LAMIN binding 
domains. It demonstrates the power of correlating un­
published genomics and epigenomics data with publicly 
available data to make interesting discoveries.
CM: A recent paper that I think demonstrates an 
impor tant point about mapping insights from functional 
genomic data in model organisms is McGary et al. [15], 
in which the authors define the concept of ‘phenologs’, 
which are pairs of phenotypes across two species that 
share a set of orthologous genes. The key observation is 
that sets of functionally related genes are often conserved 
as functional modules across species, but that their 
corres ponding phenotypes in the two species might have 
no obvious connection. Thus, after constructing a pheno­
log map pairing phenotypes across species, the authors 
show that one can accurately predict new genes related to 
phenotypes in higher eukaryotes based on functional 
genomic data from more genetically tractable model 
organ isms. For example, they identify a phenolog con­
nect ing yeast sensitivity to the drug lovastatin to abnor­
mal angiogenesis in mice. This connection then enabled 
them to predict new genes with a role in angiogenesis 
based on yeast genes that showed the lovastatin pheno­
type, and the prediction was confirmed in the frog 
Xenopus. This is an important paper because it provides a 
model for how we can leverage the wealth of data 
produced in model organisms that are more genetically 
tractable to gain insights about higher organisms and 
disease. The method itself was very simple but based on a 
powerful idea, and is one that will work in a number of 
different contexts.
AO: A lot of my recent work has been on the analysis of 
RNA­seq data. There are many opportunities provided by 
sequencing the transcriptome that have not been possible 
with previous technologies, such as detecting all ex­
pressed transcripts in a sample and annotating them, 
determining splicing variants and how isoforms change 
between samples, looking for allele­specific expression 
and looking at RNA editing. However, I think there is still 
a lot of work to be done in order to develop analytical 
methods to capture all the different types of information 
that we might want to obtain from an experiment. Each 
type of question requires different analysis. One of the 
problems with developing analysis methods is actually 
showing that the method is doing the right thing and 
understanding possible biases and limitations of analysis 
strategies. In this context I believe a recent paper on 
spike­in standards for RNA­seq experiments will be very 
influential [16], as these sorts of data sets enable us to 
identify and study biases in data generation and analysis 
and allow us to assess and compare methods. Hopefully 
more of these ‘truth’ data sets will be generated to enable 
us to further develop our understanding of the technology.
JR: Two recent papers have shown that a long non­
coding RNA termed Coldair plays a key role in regulating 
plant flower formation [17,18]. What’s remarkable is that 
this RNA ‘senses’ temperature and indicates to the plant 
when it is warm again and time to flower. This is an 
incredible example of sensing the environment and 
making epigenetic decisions. It also highlights the impor­
tance of reading primary plant literature; discoveries in 
plant science are often a decade ahead of the curve!
MW: There are so many wonderful papers in systems 
biology, which is by now quite a large discipline. It is hard 
to nail down only one; my favorites that are destined to 
become classics include a paper from Frank Holstege’s 
group [19] that identified different network topologies 
that can ensure robustness through paralog redundancy 
in yeast genetic and signaling networks. This paper is a 
beautiful example of true, integrative systems biology 
that takes advantage of different techniques, available 
datasets and modeling to gain systems­level insights into 
signaling network architecture. The second paper is from 
Karen Oegema’s group, in collaboration with Fabio Piano 
and Kristin Gunsalus [20]. This paper utilizes the power 
of systems biology in the worm by combining phenotypic 
profiling with high­resolution imaging of defects in the 
gonad, and a new clustering method that provides 
unprece dented specificity. Numerous functional anno­
tations of genes were obtained by delineating more than 
100 distinct and highly detailed gonadal phenotypes.
Who has had the most influence in your career so far?
DA: I have worked with many wonderful colleagues. I’ve 
fed off the contagious enthusiasm of Jos Jonkers [21] and 
Jonathan Flint [22] from Amsterdam and Oxford, 
respectively. Both of them are outstanding scientists and 
fabulous collaborators who never seem to tire and always 
make me do better science. At the Sanger Institute, I’ve 
been fortunate to work with Louise van der Weyden. No 
experiment is too difficult or demanding for Louise, and 
what she doesn’t know about the study of cancer genes in 
mice is not worth knowing! I’ve also learnt a lot from 
several people who I’ve worked with who were incapable 
of managing people. While I’m sure I don’t always get it 
right, I try hard to motivate people with the carrot rather 
than the stick and to make the lab a happy place to work.
BB: I would say there were three people who have most 
influenced my career thus far, one mathematician and 
two biologists: my postdoctoral mentor Daniel Kleitman 
[23], who was Professor of Applied Mathematics at MIT, 
told me ‘Proteins, that’s what you should do!’ when I was 
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looking for interesting areas to apply my algorithms 
back ground ­ he encouraged me to initiate comparative 
genomics; Jonathan King, also at MIT [24], who taught 
me much about protein folding and helped guide my 
group meetings through the first years; last but not least, 
Peter S Kim, President of Merck Research Laboratories 
[25], who worked tirelessly with me to define the new 
brand of research and publications in the burgeoning 
field of computational biology.
OH: I am happy and fortunate to have worked with 
several brilliant and enthusiastic scientists, but I acknow­
ledge the wonderful interactions I have had with Dr Kelly 
Frazer [26] for the past 4 years. Beyond a fully accom­
plished genomic biologist, she has been an exemplary 
mentor, concerned both with traditional academic train­
ing, such as grant application and scientific communi­
cation, and also with more practical mentoring on how to 
manage successful and highly collaborative genomic 
projects.
CH: Definitely my PhD and postdoctoral adviser, Olga 
Troyanskaya [27]. Just like we all grow up to resemble our 
parents, I’ve academically inherited much of Olga’s lab 
management style. Although we’re working in very differ­
ent scientific areas now, my approaches to mentoring, 
organization and presentation remain heavily influenced 
by hers at Princeton. In terms of scientific content, I give 
a great deal of credit and respect to Dirk Gevers at the 
Broad Institute [28], who’s been a phenomenal collabor­
ator on many of the projects my group has tackled since 
starting my own lab. The best collaborations are with 
folks who both know the science and have fun doing it, 
and Dirk and his team have been stellar on both counts.
SL: Three people had the biggest influence on my 
career. The first is my PhD mentor, Jun Liu, who showed 
me the fun of methodology development in computa­
tional biology, which convinced me to adopt an academic 
career. Jun has continued to help me over the years in 
research projects and career decisions, and taught me 
how to be a good mentor. The second person is my first 
collaborator, Jason Lieb, from whom I learned a lot about 
writing, leadership, and working as a team in a consor­
tium. Last but most importantly, I had a great collabora­
tor, Myles Brown [29], now at Dana­Farber Cancer 
Institute. We started collaborating in 2004, and have 
published 26 papers together. Both of us are passionate 
about new genomic technologies and gene regulation 
questions, and it is really fun working together. We brain­
storm on how to better adopt new genomic techniques, 
generate the data, develop the computational method, 
and apply them to important biological problems. I have 
learned so much from Myles and his postdocs, and some 
of our postdocs continue to collaborate with each other 
after they become independent. Myles is really generous 
in giving credit and resources to my group. He is also a 
role model for balancing work and life, and has given me 
much good career and life advice.
CM: My PhD advisor, Olga Troyanskaya [27]. I started 
my graduate studies at Princeton with an entirely 
computational background and with little direction in 
terms of my research focus, other than being interested in 
machine learning, signal processing and data mining. Olga 
introduced me to the exciting genomics revolution that 
was well underway and was willing to take a chance on me, 
even though I knew very little biology and had no previous 
experience in computational biology or bio infor matics. In 
her mentoring, Olga emphasized estab lish ing a solid 
foundation in computer science and statistics but also 
developed our skills to identify relevant and impactful 
biological questions, one of the biggest challenges of 
transitioning from a computer scientist to a ‘computational 
biologist’ in my opinion. She established a lab environment 
at the Lewis­Sigler Institute for Integra tive Genomics that 
was centered on collaboration with experimentalists and 
developing practical bioinformatics solutions to problems 
faced in these collaborations. This perspective perma­
nently shaped me as a scientist, and I certainly would not 
be where I am today without Olga’s mentoring.
AO: I have been very fortunate to have several great 
mentors in my career so far who have all been very 
influential over different aspects of my life and career. It’s 
very hard to single out people but I will just focus on two. 
Firstly, my PhD supervisor, Professor Rachel Webster 
[30], has been very supportive of me and my career, 
giving me advice and guidance for the last 15 years. I did 
my PhD in astrophysics and when I was considering 
leaving the field she fully supported that decision. Since 
then she continues to both share her experiences and 
give me advice on many issues that are important to a 
research career, such as leading a research group, con­
duct ing collaborations, managing my time, employing 
people, and effectively combining a family and a success­
ful career. Even though we no longer work in the same 
discipline, I value highly her experience and advice and 
make an effort to catch up with her every few months. 
The second person who has had a major influence on my 
career is Professor Gordon Smyth [31]. He was the one 
who first gave me a postdoc position in bioinformatics 
even though I had no specific background in the area. He 
taught me the ropes of bioinformatics and statistics and 
guided me through the initial years in this field. I will 
always be grateful to him for taking that initial risk on me 
as I find genomics absolutely fascinating.
JR: It’s almost impossible to single out one person. My 
career has been guided by amazing mentors such as 
Michael Snyder, Howard Chang and Eric Lander [32­34]. 
Outside of my mentors, Linus Pauling had a strong influ­
ence on me scientifically. I was motivated by him early in 
my undergraduate chemistry training. His work was an 
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infectious balance of scientific vigor and rigor, analytical 
yet creative interpretation with pioneering vision. His 
profound scientific contributions were equally met with 
his political importance. His humble upbringing, ability 
to admit when he was wrong, and persistence for what 
was right has continued to inspire me.
MW: My postdoctoral mentor and friend Marc Vidal 
[35]. He is very creative and has an open, yet critical, 
mind. He continues to push the envelope in the field 
while sticking to his ambitious objective to attain com­
plete protein­protein interaction networks in a variety of 
model systems.
What advice would you give to young scientists 
starting off in a research career today, or what 
advice would you give to your younger self?
DA: Science needs to be your passion and you really need 
to love it and jump in with both feet. I’m not talking 
about turning up and doing a few experiments between 
coffee breaks but making your science one of the most 
important things you do. I don’t know of any successful 
scientist who periodically doesn’t find themselves spend­
ing virtually every waking hour in the lab or in their 
office. Surrounding yourself with people who are smarter 
than you also helps you raise your game.
BB: Published is better than perfect: it’s advisable to 
communicate intermediate results while you work to 
polish your system. Also, computational biologists should 
try to become familiar with wet lab work in their chosen 
area of research. Lastly, make the algorithms you develop 
available through tools that others can easily use.
OH: Beyond showing the necessary scientific achieve­
ments through regular publication, I would emphasize 
the importance of communication. Communication is 
crucial to build a network and learn important lessons for 
a successful scientific career. Talk to your mentor(s) with 
an open mind and build a trusted and honest relationship 
with your colleagues. I have seen too many people frus­
trated due to communication issues with their mentor or 
colleagues. Big science is team science. If it does not work 
out, it is OK to move on. No one can blame you for it, as 
long as you are honest with yourself and others. Also, be 
curious of other people’s work. When going to a couple 
meetings a year, make sure you talk to the senior investi­
gators whose work you admire, and do not hesitate to tell 
them so. The next thing you know they will be writing 
you support letters and becoming collaborators.
CH: Stereotypes are often true, both the good ones and 
the bad ones. As a faculty member, there can be a lot of 
politics, you do spend a lot of time asking for money, and 
you are even busier than you were before. But on the flip 
side, you really can ‘do anything’, both in terms of choos­
ing exciting scientific directions and in shaping your 
group and your environment. If there’s a question you 
want to work on, you can ­ there’s nothing to stop you 
except your own motivation to recruit a team and fund­
ing for the investigation. And there’s no one right way to 
do it ­ lab size, teaching/training balance, approach, 
methods, impact and sales pitch are all up to you. Take 
advantage of your time as a student or postdoc to do as 
much of your own work as possible, though, since you’ll 
likely have fewer and fewer chances to perform the 
investigations with your own hands as time goes on.
SL: In computational biology, you need to appreciate 
the biology as much as, if not more than, the statistical 
method or computer science. Computational genomics is 
an applied science with strong technology components. 
When starting out, get your hands as ‘dirty’ as possible 
and as quickly as possible with data; that is, dive into big 
datasets. Without seeing enough data in detail and 
understanding the data characteristics, you won’t be able 
to develop good computational biology algorithms. Find 
a good and niche research direction that: (i) is important 
in the long run; (ii) you have a real interest in; (iii) 
maximizes your existing expertise (for example, previous 
training) and advantages (for example, timing, location, 
connections and other available resources).
CM: My advice to young computational biologists is 
that the key to success in our field is to remain grounded 
in specific biology questions, particularly ones that are 
pursued in collaboration with experimentalists. The 
success of our field is ultimately measured by the impact 
we can have on our understanding of biology, and how 
we spend our time should reflect that. In my opinion, too 
many computational biology researchers are working in 
isolation on marginally relevant problems or making 
incremental improvements in areas that have already 
been well­populated by methods that are already ade­
quate. Meanwhile, there are pressing ‘big data’ challenges 
being faced by our experimental colleagues, including 
everything from collection and normalization of massive 
datasets to scalable methods for integration of hetero­
geneous data types. Often such collaborative projects 
involve some amount of what is often considered service 
work (for example, processing/normalization of raw data, 
applying existing tools to new data, and so on), but this 
requires computational expertise and can have a major 
impact. Furthermore, contributing our efforts to these 
service­oriented tasks almost always leads to exciting 
new issues and methods that generalize to other scenarios. 
The most exciting and impactful research is being accom­
plished by synergistic cross­disciplinary teams, so if you 
want to have an impact get involved in this sort of 
research. Finally, remember that building collaborative 
relationships takes time ­ establishing the specific 
relevant expertise, effective communication and trust 
that are necessary for successful collaborations is hard 
work ­ but investing time in honing these skills will pay 
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off and can serve as the basis for a successful and 
rewarding career.
AO: I think one of the most important skills in research 
is the ability to communicate ideas. My advice would be 
to spend time practicing both writing skills and oral 
presentation skills. There is no point making great 
discoveries if no one knows about them or uses your 
discoveries. Therefore, your ideas need to be communi­
cated effectively. I think it is very important to under­
stand the audience that you are communicating to and 
work out effective ways to explain concepts, especially in 
the current environment where there are many multi­
disciplinary teams with different background knowledge. 
What may seem obvious to you may not be obvious to 
other people that are potentially interested in your work. 
Some people have a natural talent for communicating 
their ideas but for the majority of us it’s something we 
need to spend time working on. My way of doing this, at 
least initially, was to look at papers that I really like 
reading and work out why I think they are good and try 
to emulate the style in my own work. With regard to oral 
presentations, I always practice them out loud several 
times and try to get feedback from colleagues on which 
parts worked and which weren’t clear or interesting.
JR: I try not to give too much advice as I have seen many 
diverse paths met with great success in science. If there 
was one thing, I would say it’s the ability to understand 
both the experimental and the computational sciences. 
Modern biology is becoming a seamless integra tion of 
these two disciplines. If trained as an experi menta list, I 
would learn the key principles in compu tational biology or 
at the very least the linguistics, and vice versa.
MW: Put yourself ‘out there’: ask questions at meetings, 
build a scientific network with colleagues, do not sacrifice 
quality for quantity of data. Be fearless and ask hard 
questions ­ and try to answer them!
What in your opinion are the top three challenges 
in your field right now (and what progress is being 
made to address them)?
DA: In cancer genetics the biggest challenge is integrating 
data from genome sequencing, transcriptomes and the 
epigenome, so that it makes sense. The problem is no 
longer acquiring the data but ‘embracing the chaos’. Some 
of the Boolean logic approaches are making inroads in 
this area. In mouse genetics, it’s all about engineering the 
mouse genome faster. The TAL nucleases, which can be 
used to tailor the mouse genome with base­pair 
precision, potentially represent a big advance in this area, 
but we need to understand if they have off­target activity. 
In genome sequencing, read length really matters for 
assembly and while the last few years of short­read 
sequencing have been amazing we really need long­read 
technology that is truly scalable and accurate (and cheap).
BB: The mission of computational biology is to answer 
biological and biomedical questions by using computa­
tion in support of or in place of laboratory procedures, 
with one goal being to get more accurate answers at a 
greatly reduced cost. Three major emerging challenges 
are: how to make sense of massively accumulating data, 
how to develop reasonable gold standards for testing our 
algorithms, and how best to integrate computational 
studies with real biological experiments (on both sides).
The past two decades have seen an exponential increase 
in genomic and biomedical data, which will soon outstrip 
advances in computing power to perform current 
methods of analysis. Extracting new science from these 
massive datasets will require not only faster computers; it 
will also require smarter algorithms. Moore’s Law has 
been a great friend of computational biologists: the 
amount of processing you can do per dollar of compute 
hardware is more or less doubling every year. Back in the 
1990s, the growth rate of genomic data was balanced by 
the growth rate of computing speeds. However, one way 
this balance is being disrupted is by the advent of next­
generation sequencing. The size of genomic databases is 
going up by a factor of 10 every year, far outstripping the 
growth in our computational capacity. It’s tempting to 
think that cloud computing is going to solve this problem, 
but that’s not the case. It doesn’t change the problem that 
the data are increasing exponentially faster than comput­
ing power per dollar. The only solution is to discover 
fundamentally better algorithms for processing these 
databases. Better algorithms can make an enormous 
difference. In fact, you’ve got to devise algorithms that 
are so fast that, in some cases, they can’t even grow 
linearly in the size of the databases.
Another big challenge in computational biology is the 
determination of gold­standard datasets for training 
compu tational techniques. For example, consider the 
problem of determining orthology relationships across 
species. What we really want to identify are functional 
orthologs (that is, genes that perform the same functions 
across various species). Direct experimental data about 
this are scarce. The most commonly available datasets 
capture this only indirectly by looking at, say, sequence 
similarity between the genes. There are many computa­
tional approaches that use this indirect data to predict 
such orthology relationships, but determining which one 
works best is difficult. One direction we have been 
explor ing is using protein and genetic interaction data to 
improve orthology prediction by better capturing func­
tion correspondence. It would really help if we had even a 
limited set of proteins for which gold­standard orthology 
information was available. All the computational tech­
niques can then be better trained. However, we are still 
some distance away from having any gold­standard 
orthology sets. There are many other problem domains 
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where being able to generate good gold­standard datasets 
would significantly improve our ability to use computa­
tional methods.
The final challenge is the need to improve the integra­
tion of biological and computational methods. In some 
domains, algorithmic thinking is already very tightly 
integrated into the process of experiment design, execu­
tion and interpretation. Genome sequencing is a great 
example of where such integration has yielded great success. 
In other cases, however, biological methods use compu­
tational analysis only as an afterthought; for example, 
many studies of cell signaling could benefit greatly from 
having knowledge of innovative computa tional techniques 
applied early in the design stage, so that the right data are 
available to enable the full power of these methods to be 
applied. The converse of this criticism also applies to 
computer scientists. We need to have a better under­
standing of the subtleties of various biological experiments. 
Far too often, enough biological details are abstracted 
away so that the solution loses its biological relevance.
OH: Access to adequate clinical research samples in 
cancer genetics is one of the most important challenges 
in cancer genetics. Collection of samples by biopsy or 
surgical resection has been traditionally performed for 
clinical care only. It is currently extremely hard to use the 
same samples for research for various reasons, from 
preparation methods, to logistic or consent. Several 
institutions like the University of California, San Diego 
are developing master protocols to systematically consent 
a majority of oncology patients and collect samples from 
surgery or biopsy for investigational purposes. The resis­
tance is high, in general legitimated by the patient’s 
protection, but people start to understand that it is the 
only way to eventually deliver the promises of personal­
ized diagnostics and care.
Another challenge is to educate people about genomics 
and to tone down the natural hype of the genomics field. 
Investigators involved in clinical and translational projects 
are in some way victims of the hype created by the 
fantastic and recent technological advances. I frequently 
talk to clinicians who are enthusiastic about sequencing 
their samples, but many projects often fall short due to 
the ignorance of the requirement of sample number or 
quality. For example, there is no good rationale to 
sequence the whole genome of thousands of samples 
except to make it a general resource for the community. 
Biological questions might be better addressed with a 
more focused approach, such as sequencing exons or 
candidate regions in properly selected patients. The hype 
of the sequencing field is a wonderful catalyzer of novel 
ideas and provides much needed public exposure of our 
field, but we have to regularly educate prospective 
collaborators on basic notions of genetics or the reality of 
the sample preparation or data analysis. At our 
institu tion, my function in the University of California, 
San Diego, Clinical and Translational Research Institute 
(a Clinical and Translational Science Awards funded 
entity) [36] is to do just that: consult with people and 
help them with the design, preparation and analysis of 
their trans lational genomic experiments.
Finally the last challenge is to transform the academic 
review system in our institutions. Traditional institutions 
expect faculty to lead independent projects typically 
funded through the R01 NIH grants. However, genomics 
has traditionally functioned differently, following the 
principle of team science, where multiple principle 
investi ga tors contribute to a large endeavor. This was the 
case for the Human Genome Project and The HapMap 
project, and today the 1000 Genome Consortium and 
The Cancer Genome Atlas, for example. This ‘big science’ 
is usually financed through alternative sources of funding 
requiring collaborations and multiple principle investiga­
tors, and the results do not always lead to first or last 
author publications for the majority of the participants 
despite their essential roles. Traditional institutions that 
promote faculty based on R01 awards and last author 
publications do not always recognize this aspect. This 
divergence does not favor the retention of brilliant 
researchers in academic genomic research. Some institu­
tions, such as Harvard or The Ontario Institute for 
Cancer Research, have established alternative academic 
review criteria that recognize participation in team 
science and allow investigators to successfully grow in 
this environment. At the time when funding is becoming 
scarce and more directed to specific projects, let’s hope 
that more institutions will follow these examples.
CH: (i) Understanding the systems­level ecological rules 
governing microbial community structure, (ii) relating 
the human microbiome to health and disease, and (iii) 
streamlining methods for turning next­generation data 
into actionable biology. Addressing the combination of 
the first two challenges will help us realize some of the 
human microbiome’s potential as a means of diagnosis 
and therapeutic intervention. Investigating the first 
challenge in particular should let us leverage systems 
biology’s successes in molecular biology during studies of 
microbial communities. The second will likewise feed 
back into the broader metagenomics community by 
identifying ‘interesting’ microbiome properties, environ­
ments and phenotypes on which to focus. Finally, the 
third challenge includes finding ways to collaborate on 
biological ‘big science’ projects, to collectively analyze 
sequence data (of all sorts, not just metagenomic), and to 
leverage shared computing resources. All of these con­
tinue to be necessary to solve the considerable data 
management and interpretation challenges brought about 
by next­generation sequencing technologies. These tech­
nologies will continue to accelerate biological 
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discovery  ­ but there are still many opportunities for 
computational methods to accelerate that acceleration.
SL: Now that it’s possible to profile transcription factor 
binding using ChIP­seq, the ability to predict the target 
genes and the direction of their expression changes upon 
factor activation or inactivation is still an important 
challenge. For factor binding, there are often thousands 
of genes nearby binding, but only a minority of the 
nearby genes really show differential expression and we 
don’t know why. Also, for transcription factors with 
multiple functions such as CTCF (for example, trans­
criptional repressor and insulator) the challenge is 
whether we can differentiate their functions from ChIP­
seq of other factors or histone marks. Approaches such 
as HiC and ChIA­PET can identify genome­wide higher­
order chromatin interactions, which have the potential to 
answer this question, although there are still technical 
and cost challenges for these techniques to be widely 
adopted.
Performing ChIP­seq or DNase­seq with a small 
amount of starting material is a challenge. Currently one 
needs 100,00 to 500,000 cells to do a histone mark ChIP­
seq, and 1 million to 2 million cells for transcription 
factor ChIP­seq. To make ChIP­seq or DNase­seq work 
well on tissues or tumors, it is important to start from 
smaller numbers of cells. The laboratories of Peggy Farn ham 
[37] and Brad Bernstein [38], and many other labora­
tories, have explored this issue. Recently the Gronemeyer 
group published a new method to linear amplify pico­
gram DNA [39]. Commercial companies like Illumina are 
developing kits for library construction from <1  ng of 
DNA, and third­generation sequencing techniques 
promise to offer a better solution to working with small 
amounts of starting material.
Finally, there are many transcription factors, chromatin­
modifying enzymes and histone marks functioning 
together to regulate gene expression. The specificity (for 
example, which transcription factors specifically recruit 
which histone marks or histone modifying enzymes) and 
the cooperativity (for example, which factors are pioneer­
ing factors for the binding of other factors) of these factors 
in different cells or conditions are still poorly understood. 
Without understanding this, the effect of epi genetic drugs 
could be hard to interpret. As sequen cing technologies 
increase throughput, multiplex ChIP­seq would allow us 
to investigate many more conditions in combination and 
we might have a better answer for this question.
CM: In my specific area of interest, genetic interaction 
networks, there are a few challenges we face as a 
community. (i) Scalable technology for mapping genetic 
interactions for other phenotypes, conditions and organ­
isms, especially higher eukaryotes. The yeast community 
has been very successful in the past several years at 
develop ing technology for rapid construction of 
combi na torial mutants to map genetic interactions. 
Specifically, the typical approach is to look for combi na­
tions of muta tions that result in a surprising phenotype 
(usually fitness defect) given the phenotypes of the 
mutations introduced independently. These efforts have 
produced global inter action maps covering millions of 
combinatorial mutants, which have proven to be quite 
useful for understanding gene function and general 
organization of the cell. In yeast, efforts are underway to 
expand these maps to other phenotypes and other 
conditions; this requires new scalable technologies given 
the space of possible experi ments. Such maps in higher 
eukaryotes will be important for understanding the 
genetic basis for complex pheno types and disease and 
developing new therapeutic approaches, but the tech­
nology for mapping these inter actions is still relatively 
limited in throughput. Several exciting efforts are under­
way to address this challenge, most of them leveraging 
RNA interference technology. The past year has produced 
new successes in Drosophila and human cell lines but 
continued focus on improving and scaling the technology 
will be fruitful. (ii) Translating insights about genetic 
interactions from perturbation studies to questions in 
population genomics. The focus of the genetic interaction 
community has largely been on precise combinatorial 
genetic perturbation in single indi vi duals (for example, 
standard lab strains). This approach is attractive because 
the effects of perturbations can be studied in a controlled 
genetic background. However, we would ultimately like 
to leverage this knowledge about how genetic variations 
combine to influence phenotype to understand the link 
between genotypic and phenotypic variation across 
individuals in a population. The latter challenge is of 
course the main goal of genome­wide association studies 
in humans; to date these have strug gled to explain large 
portions of the heritable phenotypic variation. Applying 
insights derived from large­scale perturbation studies to 
the population genomics ques tions will be an interesting 
direction, especially as the mapping technologies become 
more feasible in higher eukaryotes. There are new 
opportunities and the neces sary data to make progress 
on this front in yeast with the recent sequencing and 
phenotyping of several Saccharo myces cerevisiae strains. 
The combination of this infor ma tion on genomic and 
phenotypic variation, combined with extensive functional 
studies on the reference genome, will provide a good 
testing ground for new methods in this area. (iii) 
Leveraging functional genomic data across species. As I 
noted above, a more general challenge is the problem of 
leveraging functional genomic data across species to 
speed the process of functional characterization. Even 
the most basic question in systems biology, ‘What are all 
of the genetic components related to biological process 
X?’, has not been answered comprehensively in most 
Genome Biology 2011, 12:137 
http://genomebiology.com/2011/12/12/137
Page 7 of 11
species, particularly in higher eukaryotes. Enormous 
resources have been spent generating functional data in 
model organisms, but these data are relatively 
underutilized for mapping functions in other species. 
The paper from McGary et al. [15] provides a nice 
demonstration of how insights from relatively data­rich 
model systems can be used to direct experi mental 
investigation of genes related to specific pheno types in 
more complex organisms, and I suspect similar 
approaches can be developed in other settings. Accom­
plish ing this will require new computational infra­
structure and tools to support integration and compara­
tive analysis of functional genomic data.
AO: Getting a handle on the propensity and type of 
RNA editing that is occurring is a fascinating area which, 
as yet, has not been fully resolved [40]. It has been 
documented that the sequence of RNA can be modified 
post­transcriptionally, resulting in an RNA sequence that 
is different from the DNA from which it was derived. 
High­throughput sequencing technologies give us the 
opportunity to study RNA editing on a genome­wide scale 
and there have been several publications recently on this 
topic [41,42]. However, there is quite a debate about how 
frequently this actually occurs. In my view, results are 
probably influenced by biases in mapping procedures (see 
Joe Pickrell’s blog [43] and the recent paper by Schrider et 
al. [44]) and it will be fascinating to see how this debate 
gets resolved in the near future and what the results mean 
for the diversity of the transcriptome.
There are many projects producing massive amounts of 
sequencing data. One of the major scientific challenges 
right now is the integration of different types of data to 
explain a biological phenomenon. For example, the 
ENCODE project is producing genome­wide expression, 
trascription factor and epigenetic data on many different 
cell types [45]. Making sense of even just a small fraction 
of these data sets is extremely challenging and will 
require major breakthroughs in analysis and interpreta­
tion. In particular, I believe the integration of epigenetic 
and expression data will be a major challenge over the 
next few years and there are many specific questions that 
are unresolved. There are two questions that I think are 
particularly interesting in the area of data integration. (i) 
How can we describe the epigenetic landscape and how 
is it related to development and disease? There are over 
100 epigentic histone modifications known to date and 
more are being discovered all the time. Therefore, there 
are millions of possible epigenetic combinations that 
could be predictive of expression and function, and most 
probably only a small fraction of these are important, 
however. Recently there has been some excellent work 
published on combining epigenetic marks to annotate 
the genome [46,47]. (ii) How is alternative spicing con­
trolled and what is the role of epigenetics? 
Next­generation sequencing has shown that many genes 
in the genome have multiple isoforms; however, the 
mecha nisms that control the switching between 
alternative transcripts are not well understood. Recently 
there have been extremely fascinating observations that 
show an important role for epigenetics in controlling 
splicing events (for example, [48,49]). There is still a long 
way to go in order to try and integrate epigenetic and 
expression data on a genome­wide scale.
JR: (i) What properties of large non­coding RNA genes 
would identify subfamilies and classes? Imagine the text 
book had already been written for non­coding RNAs and 
someone recently discovered protein genes. One of the 
first things to do is identify functional domains (for 
example, helix­loop­helix, DNA­binding domains, and so 
on) that could be extrapolated to families related by 
functional properties. With RNA it’s a bit trickier but 
initial progress is being made for large non­coding RNAs 
using co­expression with proteins, a process termed ‘guilt 
by association’. We recently got a glimpse of some of the 
first emerging global properties after mapping and 
characterizing 8,000 long non­coding RNAs [50]. They 
are strikingly more tissue­specific than protein­coding 
genes, an interesting feature that we could potentially use 
in medical diagnostics. (ii) Why is there so much non­
coding RNA? It’s clear that there are numerous functional 
large non­coding RNAs but almost the entire genome is 
transcribed. Progress is being made by more global loss­
of­function and gain­of­function experiments. (iii) What 
do these non­coding RNAs do and how do they do it? We 
have identified an emerging theme of non­coding RNA 
interacting with proteins and modulating their function. 
These RNA­protein complexes are important for main­
tain ing cellular identity. We need to further understand 
the structural and functional elements that drive these 
interactions. If we could learn how these RNAs work, we 
could envision engineering them to guide stem cells into 
distinct cell types.
MW: (i) Single cell systems biology: many labs are 
making good progress toward this, from cell biological 
imaging screens, to measuring parameters in single cells. 
This will result in high resolution of biological infor ma­
tion and will provide important insights into cell­to­cell 
variability in cellular networks. (ii) Dynamic networks: 
currently, many available networks collapse all measured 
interactions into a single graph. However, it is clear that 
only parts of the network are active in different cells or 
under particular conditions. Therefore, we need to start 
including spatiotemporal components of networks and 
their activity. Visualization is an important component of 
this, as is measuring reaction kinetics and the concen tration 
of different biomolecules. (iii) Developing integra tive 
networks that combine metabolism, protein­protein inter­
actions, genetics and regulatory networks. So far, most 
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studies focus on a single type of network. However, it is 
clear that many biological processes are controlled by a 
flow of information through different types of mole cules, 
and thus networks, and often result in differences in 
cellular and organismal metabolism. To better capture 
the events important to a biological process, it will be 
important to combine all relevant, active networks into a 
single graph
If money were no object, what study would you 
love to perform?
DA: If money were no object, I’d sequence all the athletes 
in the Olympic village and all the dogs at Crufts!
BB: I would do much larger­scale genome­wide asso cia­
tion studies to have sensitivities at the levels of small 
multifactorial effects (that is, leverage statistical power to 
be able to detect a signal in millions of human genomes 
that isn’t currently distinguishable from noise). Assuming 
one can do the analysis efficiently with my lab’s com­
pressive genomics paradigm, whole genome sequences 
offer the ability to directly infer causal variants, as opposed 
to single­nucleotide polymorphisms, which currently just 
map marker regions (using linkage dis equilibrium) to 
phenotypes. I would also like to do a genome­wide 
epigenome scan for discordant twins, to find out why they 
are different despite near identical genomes.
OH: I would study cancer genetics at a much higher 
resolution: at the single­cell level to study the process of 
clonal evolution and selection; at the environment or 
niche level to study the effect of the stroma and surround­
ing cellular environment on cancer progression; and 
finally, at the diploid level to determine the differential 
role of each allele in cancer progression. I’d start by address­
ing the technical challenges of single­cell genomics.
CH: There are two directions in which I’d like to go 
with such a grant, one computational and the other 
trans lational. The former is a bit prosaic, in that the field 
has now completed enough human microbiome projects 
to have a good idea of what data and metadata are useful. 
We need to develop a platform to standardize and 
automate the process of boiling microbial sequence down 
to functional information, then comparing that to subject 
phenotype, much as has been done successfully for 
environ mental metagenomes up to this point. Trans­
lationally, this would enable a sustainable effort to track 
the human microbiome longitudinally, in a large 
prospective cohort. Epidemiology in such cohorts has 
been uniquely successful in characterizing dietary and 
environmental influences on health; the microbiome is a 
big component of our everyday environment that’s so far 
not been assessed in such a manner. Building and 
maintaining such a cohort over time would take more 
than just my group and a few million dollars, but it’s a 
project I’d be excited to see happen soon!
SL: I would examine the epigenetic status at regulatory 
sequences (especially enhancers) and see how this 
changes between conditions (for example, development, 
stimulation and drug treatment) and between individuals 
(for example, tumor tissues).
CM: I’d invest in tools for perturbing and characterizing 
mutants derived from a reference ‘normal’ human 
genome, so that we could enable true systems biology in 
humans. To do this, we’d need to improve technology for 
single and combinatorial knockdown of transcripts 
genome­wide, quantitative read­outs for various cell 
states (for example, transcription levels, protein levels, 
protein/chromatin modifications, protein­protein inter­
actions) and single­cell quantitative phenotyping. In 
addition to improving the technology on all of these 
fronts, I would invest significant resources in applying 
them systemati cally and globally on a set of carefully 
chosen reference cell lines. I think the only way we will 
understand how the genotype determines phenotype ­ 
the basis of human disease ­ is through systematic 
functional genomics.
AO: As I’m interested in epigenetics and gene regula­
tion, I would love to spend some money building up 
interesting epigenetic and expression data sets using 
ChIP­seq, RNA­seq and DNA­seq to look at histone 
modi fi cations, transcription factors, RNA expression, 
micro RNAs and RNA­protein interactions, all with a 
large number of controls. However, I would probably 
spend most money on employing and training people to 
develop methods to analyze and visualize the data in new 
and imaginative ways and to collaborate on exciting 
projects. There are so many different possibilities for 
exploring the vast amounts of genomic data that are now 
being produced. However, I believe the biggest bottleneck 
is the bioinformatics and the shortage of researchers in 
the field. There needs to be a big investment to address 
this shortage.
JR: I would study ants and bees. Social insects fascinate 
me, and I have a hunch that maternal and/or paternal 
RNA storage might be involved in establishing which 
larva becomes a worker or a queen. More practically, I 
would use the money to perform combinatorial genetic 
engineering of stem cells, aiming to guide and tweak their 
metamorphoses into other types of cells.
MW: If money (and time!) were no object, I would 
measure all metabolites in a system of interest 
(Caenorhab ditis elegans in my case), and repeat this upon 
perturbation of gene regulatory networks by transcrip­
tion factor RNA interference and under a variety of 
environmental and nutritional conditions. Simul tan eously, 
I would measure the transcriptome under each condition. 
The data would then be used to create com prehensive 
and integrative network models that link meta bo lism to 
gene expression.
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